Sep 16, 2021

Breakthrough drug approved as alternative to chemotherapy for people with advanced lung cancer -- ScienceDaily

Pembrolizumab, an immunotherapy drug has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC). The first-line designation means that some patients will have access to the drug without first having to receive other treatments such as chemotherapy.

Proceed to the page: http://linkis.com/feANx

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent sciencedaily.com Articles

Latest Links Processed

0/120